RheinCell Therapeutics GmbH specializes in GMP-compliant manufacturing of human induced pluripotent stem cells (iPSCs) as fully characterized starting materials for "off the shelf" regenerative therapies. One of the company’s core products is a library of HLA-homozygous iPSC lines derived from rigorously selected, patient-consented cord blood units that match multiple recipients and enable the manufacture of allogeneic cell therapies with significantly reduced immunogenicity. RheinCell’s headquarters in Langenfeld, Germany, house state-of-the-art cell culture and processing facilities, as well as a services infrastructure for the development of cell differentiation protocols, rigorous characterization and release-testing of cell lines, and the establishment of cell banks in high-security storage facilities.